A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients with Essential Hypertension

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients with Essential Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Amlodipine/fimasartan (Primary) ; Amlodipine; Fimasartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 23 Jan 2013 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Additional lead trial investigator (Eun Seok Jeon) identified as reported by Korean Clinical Trials Register record.
    • 14 Mar 2012 New source identified and integrated (KCT0000192; Clinical Research Information Service (CriS) - Republic of Korea).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top